Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Mar 15, 2022; 14(3): 587-606
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.587
Published online Mar 15, 2022. doi: 10.4251/wjgo.v14.i3.587
Gut and liver manifestation | Possible reasons at diagnosis | Possible reasons during therapy | Recommendations |
Jaundice | Tumor infiltration and necrosis of hepatocytes; Obstruction of biliary system by enlarged lymph nodes; Transfusion related viral hepatitis; Consider possibility of HLH as atypical presentation of hemato-lymphoid malignancies; Sclerosing cholangitis in a case of LCH | Chemotherapy induced liver injury (e.g., 6-MP, Methotrexate); Reactivation of viral infections (e.g., HBV, HCV, CMV, EBV) | Screen for HBV, HCV, HIV before starting chemotherapy; Safe transfusion practices; Exercise pharmacovigilance (chemotherapeutic drug dose modifications with underlying hepatic impairment, therapeutic drug monitoring-e.g., Methotrexate); Screen for genetic polymorphisms (e.g., TPMT, NUDT15 genotype for 6-MP)[104]; Abdominal imaging either CT angio or MRCP with MRI on clinical basis; Prioritize chemotherapy initiation for underlying malignancy over waiting for resolution of HLH with HLH treatment protocol[105]; Initiation of antivirals before chemotherapy for hepatitis B, hepatitis C infection as per standard guidelines[106,107] |
Liver failure | Peculiar presentation with T-ALL, AML, TAM of newborn; Overwhelming sepsis at baseline due to poor immune reserve | Peculiar toxicity with L-asparaginase, high dose methotrexate and anthracyclines in predisposed individuals; Viral hepatitis especially hepatitis B reactivation | Early steroid initiation at presentation for preventing further liver cell necrosis in a case of ALL; Considering chemotherapy for TAM; FFP, cryoprecipitate product transfusions for hemostasis; Screen for hepatotrophic viral markers and appropriate antiviral therapy |
Visceral perforation | Advanced stage lymphomas causing gut obstruction; Typhlitis due to severe neutropenia (e.g., AML); Appendicitis as presentation (especially with ALL) | Post chemotherapy initiation with high grade lymphomas of stomach or intestine; C. difficile infection | Abdominal girth, bowel sound monitoring stringently in suspect cases; Abdominal imaging by CECT enterography with oral positive contrast; Stool examination in colitis for C. difficile; Anticipatory surgical consultation in advanced lymphomas |
Bowel obstruction | High grade lymphomas causing intussusception; Extrinsic nodal compression of gut | Vinca alkaloid induced paralytic ileus during therapy; Septic ileus during periods of neutropenia | Abdominal imaging with CECT enterography; Adequate broad spectrum antibiotic cover; Surgical consultation for intussusception; Continuous gastric /bowel drainage above the level of obstruction |
GI bleed | Mucosal bleed due to thrombocytopenia at presentation; GI lymphoma[77] | Thrombocytopeniainduced mucosal bleeds; Drug induced coagulopathy (e.g., peg-asparaginase); Typhlitis; C. difficile colitis | Conservative management with blood products; Laparotomy only in uncontrolled bleed for surgical resection; In suspect cases of C.difficile colitis, stool for toxin assay, GDH and consider colonoscopy |
Pancreatitis | Rare as initial presentation | Drug induced (Asparaginase preparations, cytarabine) | Do not rechallenge with the same drug in case of AAP; Genetic testing could have a future role in predicting the risk of drug induced pancreatitis |
Ascites | High grade lymphomas at presentation; Peritoneal lymphomatosis; Chylous ascites in prolonged untreated Hodgkins lymphomas; Reported cases of secondary BCS due to Burkitts lymphoma; Pancreatic ascites in severe pancreatitis | Drug induced liver failure (ex. Anthracyclines at toxic dose, L-asparaginase) | Ascitic fluid for flow cytometry and malignant cytology can provide rapid diagnosis; MCT supplementation for chylous ascites; Octreotide and TPN for refractory chylous ascites; Lymphangiography if refractory chylous ascites |
- Citation: Devarapalli UV, Sarma MS, Mathiyazhagan G. Gut and liver involvement in pediatric hematolymphoid malignancies. World J Gastrointest Oncol 2022; 14(3): 587-606
- URL: https://www.wjgnet.com/1948-5204/full/v14/i3/587.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i3.587